Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SlovakiaBack to Slovakia

Clinical trials in Partizanske

12 clinical trials in Partizanske, Slovakia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Partizanske at a glance
12
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

12 trials in Partizanske

Open in trial search

Colorectal cancer+1

Recruiting

Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
  • Sponsor:Ngm Biopharmaceuticals Inc.

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Triple negative breast cancer

Not recruiting

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Cachexia

Not recruiting

Study of ponsegromab for patients with cancer cachexia and elevated GDF-15 levels

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer+2

Not recruiting

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer stage IV

Not recruiting

Study of BAT3306 or pembrolizumab with chemotherapy (carboplatin and pemetrexed) in patients with stage IV non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bio-Thera Solutions Ltd.

Breast cancer

Not recruiting

Study Comparing ARV-471 and Palbociclib with Letrozole and Palbociclib for Patients with Estrogen Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Other cities in Slovakia

The busiest research cities in the country

All 92 cities in Slovakia

Clinical research in Partizanske

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive breast cancer treatments, particularly for patients with advanced stages of the disease. Studies are evaluating novel therapeutic combinations and comparing their effectiveness against standard treatments.

  • ER-positive/HER2-negative advanced breast cancer
  • Triple-negative breast cancer
  • ESR1 mutation studies

Multiple trials are exploring breakthrough therapies including targeted treatments combined with established medications.

02 Lung Cancer Studies

Research initiatives targeting non-small cell lung cancer through various therapeutic approaches, including immunotherapy combinations and targeted treatments for specific disease stages.

  • Stage IV non-squamous NSCLC
  • PD-L1 positive NSCLC
  • Post-surgical treatment evaluation

Studies are comparing novel drug combinations with established treatments to improve patient outcomes.

03 Specialized Conditions

Focused research on various conditions including Sjögren's Syndrome and advanced melanoma, with trials evaluating new therapeutic approaches and treatment combinations.

  • BRAF mutation-positive melanoma
  • Cancer cachexia
  • Autoimmune conditions

These studies aim to advance treatment options for specific patient populations with unique medical needs.

Back to SlovakiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.